Interferons (IFNs) were first described for their ability to protect cells from viral infections [1] . Since these initial reports, three major types of IFNs have been described. Type I IFNs, including IFNβ and multiple IFNα subtypes, induce antiviral gene programs through the IFNα/β receptor, IFNAR; many of these genes are directly or indirectly involved in curbing viral replication and spread [2] . Type I IFNs have been used to treat both chronic viral infections, such as hepatitis B and C, and a variety of neoplastic conditions, such as melanoma, hairy cell leukemia, and non-Hodgkin's lymphoma [3] [4] [5] [6] [7] . Recently, PEGylated IFNs, which show decreased clearance as compared to recombinant IFNs, have emerged as the standard of care. Although PEGylation has increased the therapeutic efficacy of IFN therapy, a wide variety of unpleasant and serious side-effects exist. In this study, we set out to determine whether antibody-IFN fusions could be used as an alternative and allow for specific targeting of IFNs, which we believe would be beneficial in reducing undesired side-effects.
Dear Editor,
Interferons (IFNs) were first described for their ability to protect cells from viral infections [1] . Since these initial reports, three major types of IFNs have been described. Type I IFNs, including IFNβ and multiple IFNα subtypes, induce antiviral gene programs through the IFNα/β receptor, IFNAR; many of these genes are directly or indirectly involved in curbing viral replication and spread [2] . Type I IFNs have been used to treat both chronic viral infections, such as hepatitis B and C, and a variety of neoplastic conditions, such as melanoma, hairy cell leukemia, and non-Hodgkin's lymphoma [3] [4] [5] [6] [7] . Recently, PEGylated IFNs, which show decreased clearance as compared to recombinant IFNs, have emerged as the standard of care. Although PEGylation has increased the therapeutic efficacy of IFN therapy, a wide variety of unpleasant and serious side-effects exist. In this study, we set out to determine whether antibody-IFN fusions could be used as an alternative and allow for specific targeting of IFNs, which we believe would be beneficial in reducing undesired side-effects.
We have previously generated chimeric molecules by fusing murine IFNα to the carboxyl-terminus of human IgG3 (IgG3-IFNα) [8] . As IFNα is a potent antiviral cytokine, we examined the ability of IgG3-IFNα to activate the antiviral response and inhibit viral replication. In addition to increasing the potency, a potential advantageous feature of antibody-conjugated type I IFN is the possibility of using the antibody specificity to target type I IFN to specific cells. Therefore, we used anti-HER2-IgG3-IFNα, in which IFNα is fused to a HER2/ neu-specific antibody, and 38C13 cells stably expressing the HER2/neu receptor (38C13-HER2). 38C13-HER2 cells infected with MHV-68-Luc were treated with IgG3-IFNα or anti-HER2-IgG3-IFNα. Luciferase activity was reduced more effectively after treatment with anti-HER2-IgG3-IFNα across a broad range of therapeutic doses ( Figure 1B, right panel) . Importantly, the difference be- tween anti-HER2-IgG3-IFNα and IgG3-IFNα was more prominent at low concentrations, suggesting that anti-HER2-IgG3-IFNα increases the effectiveness of IFNα by targeting IFNα to HER2/neu-expressing cells. When parental 38C13 cells that did not express HER2/neu were used, both fusion proteins similarly inhibited viral replication (data not shown).
We used an intranasal model of infection with the MHV-68-Luc virus, followed by bioluminescence imaging, to determine the effectiveness of IgG3-IFNα in inhibiting viral replication in vivo. We first administered 5 000 PFU of MHV-68-Luc through nasal passages and then treated these mice intraperitoneally with 25 000 units of IFNα, 25 000 units of IgG3-IFNα (10 µg), or 10 µg of IgG3 alone. Mice were imaged on day 5 ( Figure  1C ). Bioluminescence readings of mice imaged in supine and lateral positions were obtained and are presented in the left and right panels of Figure 1D . Whereas mice treated with IFNα exhibited a slight reduction in bioluminescence readings compared with IgG-treated animals, IgG3-IFNα-treated animals exhibited a statistically significant seven-fold reduction in readings obtained in either position (P<0.0001 compared with the IgG-treated group). Indeed, mice treated with IgG-IFN had significantly reduced bioluminescence readings compared with the IFNα-treated mice (P<0.05).
On day 7 after infection with MHV-68, mice in each of the three groups were euthanized, and viral burden in the lung was measured by plaque assays using lung homogenates. qPCR analysis was also used to determine the copy number of the viral genome in the lungs of infected animals. IgG3-IFNα-treated animals exhibited a 100-fold reduction in viral burden as measured by the plaque assay (P<0.05, Student's t-test). Surprisingly, treatment with IFNα provided no protection against viral burden as measured by this assay ( Figure 1E, left panel) . Similarly, viral genome content in the lungs of IgG3-IFNα-treated animals was 600 times lower than that observed in IgG-treated animals, while IFNα treatment seemed insufficient to suppress viral genome production ( Figure 1E, right panel) . Thus, IgG3-IFNα proved to be a more potent antiviral agent both in vitro and in vivo.
